Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02309177
Recruitment Status : Completed
First Posted : December 5, 2014
Last Update Posted : May 31, 2019
Sponsor:
Information provided by (Responsible Party):
Celgene

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 12, 2018
Actual Study Completion Date : September 12, 2018